Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03383419
PHASE2

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Sponsor: Baylor Research Institute

View on ClinicalTrials.gov

Summary

This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2018-03-20

Completion Date

2026-12-30

Last Updated

2026-01-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

Epclusa

If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.

Locations (3)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Duke University Medical Center

Durham, North Carolina, United States

Baylor University Medical Center

Dallas, Texas, United States